Some patients with low-grade Ta nonmuscle-invasive bladder cancer (LG Ta NMIBC) can experience recurrence after many years.

Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva.

Medically reviewed by Steffini Stalos, DO Bladder cancer occurs when cancerous cells form in the tissues of the bladder, the ...

Urine cytology is a sensitive test for the detection of recurrence of high-grade, superficial and muscle-invasive bladder cancer. However, it has low sensitivity (30%) for low-grade tumors.

BCG therapy is associated with a high frequency of side effects in NMIBC; however, when used in sequential combination with ...

Emily Campbell, a 33-year-old marketing expert based in Miami, sought medical help after noticing bloating had made her ...

Debate over labeling certain cancers as 'benign' or 'premalignant' instead of 'cancer' due to stigma and fear. Experts weigh in on potential impact ...

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will particip ...

The preeminent expert on the two-century history of what's now known as Albany Academies, McClintock spent decades ...

Some oncologists suggest that, for certain early cancers not at risk of spreading, the term “cancer” should be avoided.